Advances in the treatment of luminal breast cancer.
dc.contributor.author | Howell, Sacha J | |
dc.date.accessioned | 2013-03-15T16:49:57Z | |
dc.date.available | 2013-03-15T16:49:57Z | |
dc.date.issued | 2013-02 | |
dc.identifier.citation | Advances in the treatment of luminal breast cancer. 2013, 25 (1):49-54 Curr Opin Obstet Gynecol | en_GB |
dc.identifier.issn | 1473-656X | |
dc.identifier.pmid | 23299092 | |
dc.identifier.doi | 10.1097/GCO.0b013e32835c0410 | |
dc.identifier.uri | http://hdl.handle.net/10541/273005 | |
dc.description.abstract | Recent advances in the genomic analysis of breast cancers show promise in better defining endocrine sensitive subtypes. In addition, several key trials have recently reported results that better define the optimal sequence of endocrine agents and approaches to overcome endocrine resistance. | |
dc.language.iso | en | en |
dc.rights | Archived with thanks to Current opinion in obstetrics & gynecology | en_GB |
dc.title | Advances in the treatment of luminal breast cancer. | en |
dc.type | Article | en |
dc.contributor.department | The University of Manchester, Institute of Cancer Studies, Manchester, UK. | en_GB |
dc.identifier.journal | Current Opinion in Obstetrics & Gynecology | en_GB |
html.description.abstract | Recent advances in the genomic analysis of breast cancers show promise in better defining endocrine sensitive subtypes. In addition, several key trials have recently reported results that better define the optimal sequence of endocrine agents and approaches to overcome endocrine resistance. |